

## Supporting Information

### **Distribution of antibiotic resistance genes and their association with bacteria and viruses in decentralized sewage treatment facilities**

Jiaheng Zhao<sup>1</sup>, Bing Li<sup>1\*</sup>, Pin Lv<sup>1</sup>, Jiahui Hou<sup>1</sup>, Yong Qiu<sup>2\*</sup>, Xia Huang<sup>2</sup>

<sup>1</sup> School of Energy and Environmental Engineering, University of Science and Technology Beijing, Beijing, 100083, China


<sup>2</sup> State Key Joint Laboratory of Environment Simulation and Pollution Control, School of Environment, Tsinghua University, Beijing 100084, China

\*Corresponding authors: libing@ustb.edu.cn (B.L.) and qiuyong@tsinghua.edu.cn (Q.Y.)

Figure S1. The percent of bacterial community abundance on phylum level

Table S1. The number of different categories of bacteria-related ARGs and their relative abundance

Table S2. The relative abundance of different virus-related ARGs in samples



**Fig. S1.** The percent of bacterial community abundance on phylum level

**Table S1.** The number of different categories of bacteria-related ARGs and their relative abundance

| The categories of ARGs | The number of types of ARGs | The relative abundance of ARGs |
|------------------------|-----------------------------|--------------------------------|
| AR                     | 667                         | 64.02%                         |
| AS                     | 65                          | 26.63%                         |
| AR, AT                 | 85                          | 8.12%                          |
| ABS                    | 3                           | 1.20%                          |
| AT, ABS                | 5                           | 0.02%                          |

Note: AR, AT means that the ARG belongs to AR and AT categories; AT, ABS mean that the ARG belongs to AT and ABS categories

**Table S2.** The relative abundance of different virus-related ARGs in samples

| ARG                            | BTC_EFF | BTC_IFF | DDJ_EFF | DDJ_INF | DS_EFF | DS_INF | MA_EFF | MA_INF | TJT_EFF | TJT_INF | WL_EFF | WL_INF |
|--------------------------------|---------|---------|---------|---------|--------|--------|--------|--------|---------|---------|--------|--------|
| dfrE(trimethoprim)             | 54%     | 71%     | 86%     | 42%     | 76%    | 69%    | 7.0%   | 15%    | 22%     | 34%     | 65%    | 54%    |
| rpoB(rifampin)                 | 20%     | 1.5%    | 2.2%    | 5.7%    | 19%    | 12%    | 0      | 0      | 0.4%    | 0.3%    | 0.9%   | 0.5%   |
| gyrB1(aminocoumarin)           | 0.8%    | 1.1%    | 0.5%    | 13%     | 0.1%   | 0      | 34%    | 1.5%   | 1.4%    | 1.4%    | 19%    | 13%    |
| gyrB2(fluoroquinolone)         | 0.5%    | 0       | 0       | 0       | 0      | 0      | 3.1%   | 46%    | 4.5%    | 1.5%    | 1.7%   | 17%    |
| gyrB3(fluoroquinolone)         | 4.0%    | 13%     | 2.7%    | 6.2%    | 0      | 0      | 0      | 0      | 0       | 0       | 6.4%   | 8.5%   |
| gyrA and parC(fluoroquinolone) | 0.5%    | 0       | 0       | 17%     | 0      | 0      | 0      | 1.0%   | 4.0%    | 32%     | 0      | 0.5%   |
| vanTG(glycopeptide)            | 0.2%    | 0       | 2.0%    | 0       | 0      | 15%    | 0      | 0      | 0       | 3.6%    | 0      | 0      |
| parE1(fluoroquinolone)         | 0       | 0       | 0       | 1.6%    | 0      | 0.1%   | 0      | 0      | 43%     | 11%     | 0      | 0      |
| gyrB4(aminocoumarin)           | 10%     | 0       | 0       | 0       | 0.2%   | 0      | 0      | 0      | 0       | 0       | 0      | 0      |
| parE2(aminocoumarin)           | 7.2%    | 0       | 0.2%    | 0.2%    | 0      | 0      | 0      | 0      | 0       | 0       | 0      | 0.1%   |
| rpoC(lipopeptide)              | 0       | 0       | 5.9%    | 7.9%    | 0      | 0      | 0      | 0      | 0       | 0       | 0      | 0.1%   |
| gyrB5(fluoroquinolone)         | 0.7%    | 0       | 0       | 1.3%    | 0      | 0      | 0      | 19.30% | 0       | 2.3%    | 2.0%   | 2.1%   |
| parC1(fluoroquinolone)         | 0       | 7.0%    | 0       | 0       | 0      | 0      | 0      | 10%    | 0       | 0       | 4.5%   | 3.6%   |
| vatB(streptogramin)            | 0       | 0       | 0       | 0       | 3.8%   | 0.5%   | 0      | 0      | 0       | 0       | 0      | 0      |
| pncA(pyrazinamide)             | 0       | 0       | 0       | 0       | 0      | 0.2%   | 0      | 0      | 12%     | 11%     | 0      | 0      |
| gyrA1(fluoroquinolone)         | 0       | 0       | 0       | 0       | 0      | 0      | 56%    | 0.9%   | 0       | 0.8%    | 0      | 0      |
| parC2(fluoroquinolone)         | 0       | 4.8%    | 0       | 3.4%    | 0      | 0      | 0      | 6.1%   | 1.2%    | 0       | 0      | 0.4%   |
| gyrA2(fluoroquinolone)         | 0       | 0       | 0       | 0.3%    | 0      | 0      | 0      | 0      | 12%     | 2.3%    | 0      | 0      |
| msbA (efflux pump)             | 0.3%    | 0       | 0       | 0       | 0      | 2.1%   | 0      | 0      | 0       | 0       | 0      | 0      |